US Patent Issued to Janssen Biotech on Feb. 24 for "CD8A-binding fibronectin type III domains" (Pennsylvania, New Jersey Inventors)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,559,541, issued on Feb. 24, was assigned to Janssen Biotech Inc. (Horsham, Pa.).

"CD8A-binding fibronectin type III domains" was invented by Rebecca Hawkins (Harleysville, Pa.), Steven Jacobs (North Wales, Pa.) and Manuel Sepulveda (Princeton Junction, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications."

The patent was filed on Feb. 8, 2024, under Application No. 1...